



Y Subbarao

Technopreneurship

GEM Series

FIRST CHAPTER

Keynote Speakers



Dr. Prem Kumar Reddy
Founder, Onconova Therapeutics,
USA



Dr. Anand Govindaluri
Founder, Govin Capital,
Singapore

Agenda

- > Welcome address
- > Journey from Scientist to Startup Founder by Dr. Reddy
- > Fireside chat moderated by Dr. Govindaluri
- > Y. S. Rao Gold Medal award (<http://bionest.uohyd.ac.in/events.html>)
- > Networking

- Wednesday, April 03 [3:30 - 5:30 PM] -
BioNEST, School of Life Sciences, University of Hyderabad
Mail publications to sonali@startupacceleratorindia.in



Y. Subbarao Technopreneurship GEMS &

Gold Medal for Best Publication of Social Relevance
(organized by Startup Accelerator India & BioNest, University of Hyderabad)

Dr. Yellapragada Subbarao was a pioneering Indian biochemist who discovered the function of adenosine triphosphate as an energy source in the cell, developed methotrexate for the treatment of cancer and discovered a broad spectrum of antibiotic including tetracycline and chlortetracycline. One has probably seldom heard of Dr. Yellapragada Subba Rao but the only way to put his achievements into perspective would be to quote American author Doron Antrim "because he lived, we may be well and alive today and may live longer". Startup Accelerator India Pvt Ltd in collaboration with University of Hyderabad is organising talks by notable technopreneurs to promote innovation and entrepreneurship in the campus.

Y SubbaRao Gold Medal: The lecture series will also acknowledge the best publication with social impact in the field of Chemistry and Life Sciences and the awardee will be honoured with "Y.Subbarao Gold Medal"

Participate in the competition by submitting your publication to sonali@startupacceleratorindia.in

About the speaker

Dr. Prem Kumar Reddy, founder of Onconova Therapeutics & Professor in the Department of Oncological Sciences & Department of Structural & Chemical Biology at the Mount Sinai School of Medicine in New York, is a pioneer in the understanding of the molecular basis of cancer and the development of novel anti-cancer strategies. Dr. Reddy has discovered several oncogenes, which includes *abl*, *ras*, *fgr*, *mos*, *myb*, *myc* and *sis*. Prof. Reddy, after 20 years of discovery of *ras* oncogene has come up with a target drug molecule, Rigosertib, which is in Phase III clinical trials. He is the author of more than 200 publications and several dozen patent applications..